Diabetic Macular Edema Market valuation is set to cross USD 4,642.9 million by 2034, at a CAGR of 1.2% through 2034.

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...

Both are considered interchangeable with the reference drug ranibizumab (Lucentis, Genentech). Byooviz was approved to treat wet age-related macular degeneration, macular edema associated with retinal ...

The Global Age-Related Macular Degeneration Market was valued at US$ 11.31 billion in 2023 and is expected to reach a market size of US$ 19.72 billion by 2032 at a CAGR of 7.2% During the Forecast ...

During his tenure at Genentech, he was a key leader for the commercial build and launch of Lucentis®, the first anti-VEGF-A treatment approved for wet AMD; he served in commercial leadership ...

This study will evaluate the safety and efficacy of two dose levels (high and low doses) of the drug compared with Roche’s RHHBY Lucentis (ranibizumab) in patients with DME. Restoret was added ...

Lucentis (ranibizumab) is a prescription drug used to treat certain eye conditions. It comes as a liquid solution for injection into your eye by an ophthalmologist. The typical dosing frequency is ...